Veterinary Vaccines Market By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines, Toxoid Vaccines, Others); By Animal Type (Livestock Animals, Companion Animals, Poultry, Aquaculture Animals); By Disease Type (Viral Diseases, Bacterial Diseases, Parasitic Diseases, Other Infectious Diseases); By Route of Administration (Injectable Vaccines, Oral Vaccines, Intranasal Vaccines, Other Routes); By Technology (Conventional Vaccines, Recombinant Technology-Based Vaccines, Vector-Based Vaccines, mRNA and Next-Generation Vaccines); By Distribution Channel (Veterinary Hospitals and Clinics, Veterinary Pharmacies and Retail Stores, Online Platforms, Research Institutes and Government Organizations); By End User (Livestock Farms, Veterinary Clinics and Hospitals, Animal Research Institutes, Pharmaceutical and Biotechnology Companies, Government and Regulatory Organizations); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Veterinary Vaccines Market: Preventive Animal Health, Mass Immunisation and Next-Generation Biologics Shape Demand  – (Updated On: 20-Aug-2026)

The Global Veterinary Vaccines Market was valued at USD 12.18 billion in 2025 and is projected to reach USD 19.82 billion by 2032, growing at a CAGR of 7.2% during 2026–2032.

 

Animal health products in the United States follow a dual regulatory framework, with oversight divided between the FDA Center for Veterinary Medicine (CVM) and the USDA Center for Veterinary Biologics (CVB). The FDA regulates animal drugs, therapeutics, and biotechnology-based products, while veterinary vaccines and biologics are licensed by USDA-CVB under the Virus-Serum-Toxin Act. Veterinary biologics must demonstrate safety, purity, potency, and efficacy before receiving USDA approval.

 

The approved animal health market is dominated by major companies developing vaccines based on live attenuated, inactivated, and recombinant technologies. Zoetis maintains a strong position through advanced recombinant and subunit vaccines for livestock and companion animals. Merck Animal Health offers broad viral and bacterial vaccine portfolios along with improved delivery technologies, while Boehringer Ingelheim and Elanco continue expanding solutions for companion animals and livestock disease prevention.

 

Current development pipelines are increasingly focused on emerging disease threats and next-generation platforms. Avian influenza (H5N1) has become a major priority, with USDA supporting field safety evaluations for innovative livestock vaccine approaches. Beyond conventional vaccines, research is advancing toward mRNA-based vaccines, recombinant vector platforms, and immunotherapeutic solutions aimed at improving protection, reducing manufacturing constraints, and enhancing animal health outcomes.

 

Overall, the veterinary vaccine landscape is shifting toward precision immunization strategies, faster response capabilities, and biotechnology-driven platforms to address evolving infectious disease challenges across livestock and companion animal populations.

 

How Large Is the Unvaccinated Animal Population Behind Future Demand?

Large animal populations do not automatically translate into effective vaccination coverage. A 2025 global analysis covering 104 cattle, pig and poultry diseases across 203 reporting countries and territories estimated substantial gaps in protection for several major diseases. Among at-risk cattle populations, vaccination coverage was estimated at 16.64% for foot-and-mouth disease, 33.80% for lumpy skin disease and 11.57% for anthrax. Coverage among pigs was only 6.56% for classical swine fever.

Poultry also showed considerable gaps. The same analysis estimated that 17.62% of at-risk poultry were vaccinated against Newcastle disease, 16.71% against infectious bronchitis and 15.04% against infectious bursal disease. These figures highlight that vaccine demand is driven not only by animal population size but also by the extent of unmet immunisation needs across production systems.

Coverage gaps are influenced by veterinary-service capacity, government funding, farmer affordability, disease surveillance, cold-chain infrastructure and access to quality-assured vaccines. WOAH's 2025 assessment of global animal health similarly reported that access to livestock vaccines remains uneven and that financing and implementation difficulties continue to affect disease-control programs.

This creates different commercial conditions across countries. Intensive poultry and swine operations can concentrate large vaccine volumes among a relatively small number of integrated producers, whereas cattle, sheep and goat vaccination in fragmented agricultural systems often depends more heavily on government campaigns and field veterinary networks.

 

Why Does Foot-and-Mouth Disease Represent One of the Largest Vaccine-Volume Opportunities?

Foot-and-mouth disease demonstrates the extraordinary scale that veterinary vaccination can reach. More than 2 billion FMD vaccine doses are used globally each year for outbreak control and preventive vaccination in endemic regions. The disease also affects international livestock trade, increasing the economic incentive for national governments to maintain vaccination, surveillance or emergency vaccine reserves.

FMD demand differs significantly between markets. Countries with continuing endemic or incursion risk may require recurring mass immunisation, while countries that eliminate the disease can eventually reduce routine vaccination. Brazil illustrates this transition. The country received official recognition in 2025 as free from FMD without vaccination following decades of disease-control programs. WOAH's current status information shows Brazil's territory covered by FMD-free zones where routine vaccination is not practised.

That shift does not eliminate the commercial importance of preparedness. Disease-free livestock-exporting markets still maintain surveillance and emergency-response capabilities because a new incursion can affect production and market access. The FMD category therefore combines recurring vaccine demand in endemic regions with preparedness-driven procurement such as vaccine banks and contingency stockpiles in disease-free countries.

 

Why Is Rabies Vaccination Closely Connected With Public-Health Policy?

Dog vaccination makes the veterinary vaccines market part of the broader One Health framework. WHO states that vaccination of at least 70% of dogs in at-risk areas is the accepted threshold for effectively interrupting canine rabies transmission and preventing human deaths.

Coverage remains below that level in several endemic markets. WHO reports that canine vaccination coverage in parts of Asia and Africa is commonly only 30% to 50%, creating a significant implementation gap between current immunisation and the level required for sustained elimination.

Unlike most livestock vaccines, rabies vaccination is strongly driven by public-health policy rather than purely commercial veterinary demand. Programs are typically funded or coordinated by governments, municipalities, and international health organisations, often supported by donor initiatives. WOAH vaccine-bank mechanisms further support this structure by enabling centralized procurement and distribution, allowing countries to focus resources on field delivery and mass vaccination campaigns.

As a result, rabies vaccine demand is closely tied to public-health budgets and the operational ability to reach and repeatedly vaccinate free-roaming and community dog populations at scale.

 

How Is the Veterinary Vaccines Market Structured in 2025?

Live, Inactivated and Next-Generation Vaccine Market Segmentation

Live Attenuated Vaccines account for the largest share by vaccine type in 2025 at approximately 32–35%, with a forecast CAGR of around 6.8%. Their established use in livestock, poultry and companion-animal vaccination keeps the category commercially important. Producers have decades of manufacturing and field experience with many live platforms, and the ability to generate a strong immune response makes them difficult to displace where established products already fit vaccination programs.

Inactivated Vaccines represent approximately 25–28% of the market in 2025 and are expected to expand at around 6.5% CAGR. They are particularly important where regulators and veterinarians prioritise the absence of replication by the vaccine organism. Foot-and-mouth disease is a major volume example, with most conventional FMD vaccines based on inactivated virus.

Recombinant Vaccines hold an estimated 15–18% share in 2025 but are forecast to grow faster at approximately 8.5% CAGR. Their commercial value is increasing in disease categories where manufacturers can introduce selected antigens or combine protection through recombinant platforms. Poultry provides an important example because vector and recombinant products can be incorporated into high-throughput hatchery vaccination.

DNA Vaccines account for approximately 5–7% of 2025 revenue and carry a forecast CAGR of around 9.8%, making them the fastest-growing vaccine type in the supplied segmentation. The category is still considerably smaller than conventional vaccines, but regulatory experience with veterinary DNA vaccination provides a commercial foundation for further development in disease areas where genetic platforms offer practical advantages.

Subunit Vaccines account for approximately 8–10% of the market and have a forecast CAGR of around 8.2%. Growth is connected to targeted antigen selection and increasing development of products designed around specific disease components rather than complete organisms.

Toxoid Vaccines represent approximately 4–6% of market revenue in 2025 and are expected to expand at around 6.0% CAGR. This is a comparatively mature category concentrated around bacterial toxins and established livestock or companion-animal immunisation requirements.

Other Vaccines account for approximately 5–7% of the market, with an estimated CAGR of around 6.4%. This grouping includes less widely used or disease-specific technologies that do not fit the principal vaccine categories.

Evidence from avian influenza shows how strongly conventional approaches can still dominate even as new technologies develop. A 2025 study evaluating 136 commercially available avian-influenza vaccine formulations found that 86.0% were inactivated, 52.2% were combination products, and 47.1% involved avian vaccine formulations. These figures apply specifically to the avian-influenza products studied rather than to the entire veterinary vaccines market, but they demonstrate the continued manufacturing importance of conventional vaccine platforms.

 

Livestock Animals Generate the Largest Revenue Share

Livestock Animals account for approximately 45–48% of the veterinary vaccines market in 2025, making them the largest animal-type segment, with a forecast CAGR of around 6.7%. Cattle, pigs, sheep and goats create recurring demand through herd-health programs and government-supported control of diseases such as FMD, lumpy skin disease, brucellosis, PPR and classical swine fever.

The scale becomes visible in individual vaccination campaigns. India's Department of Animal Husbandry and Dairying reported cumulative vaccination coverage of 110.49 crore FMD doses, 25.36 crore PPR doses, 4.57 crore brucellosis doses and 0.70 crore classical swine fever doses as of February 2025.

Companion Animals represent approximately 25–28% of the market but carry a higher forecast CAGR of around 8.4%. Routine vaccination against rabies, distemper, parvovirus, leptospirosis, Bordetella and other infectious diseases provides repeat demand through veterinary hospitals and clinics. The commercial value per animal is typically higher than in mass livestock vaccination because companion-animal products are supplied through clinical channels rather than large public tenders.

The U.S. illustrates the size of this demand base. APPA reported 95 million U.S. households owning at least one pet in 2025, including 71 million dog-owning households and 53 million cat-owning households.

Poultry accounts for approximately 18–20% of market revenue in 2025 and is expected to expand at around 7.0% CAGR. Although revenue share is below livestock, poultry can generate extraordinary dose volumes because commercial broilers and layers are produced in short cycles and vaccinated in large groups.

The United States alone produced 9.40 billion broilers in 2025, illustrating why hatchery vaccination can support billions of individual doses even within a single national market.

Aquaculture Animals represent approximately 5–7% of the market but have a forecast CAGR of around 9.5%, the highest rate among the supplied animal categories. Expansion of intensive fish farming increases the commercial consequences of infectious disease across densely stocked production systems. USDA's current veterinary biologics registry maintains a separate catalog of licensed biologics for aquatic animals, illustrating the regulatory maturity developing around this segment.

 

Viral Diseases Account for the Largest Disease Segment

Viral Diseases account for approximately 45–50% of market revenue in 2025 and are forecast to expand at around 7.3% CAGR. This category includes commercially important threats such as FMD, rabies, Newcastle disease, infectious bronchitis, infectious bursal disease, porcine circovirus and several influenza-related diseases.

The share reflects both disease diversity and the limited therapeutic options available after infection for many economically important viruses. Prevention therefore carries a particularly strong economic value for producers exposed to high-mortality or trade-restricting outbreaks.

Bacterial Diseases account for approximately 30–35% of 2025 market revenue and are expected to grow at around 6.8% CAGR. Vaccination against leptospirosis, Bordetella, clostridial infections, Salmonella and other bacterial diseases also connects directly with antimicrobial stewardship because prevention can reduce some disease episodes that would otherwise require antibiotic treatment.

WOAH reported a 5% decline in antimicrobial use in animals between 2020 and 2022 and continues to identify vaccination, surveillance and prevention as important components of antimicrobial-resistance strategies.

Parasitic Diseases represent approximately 8–10% of the market and carry a forecast CAGR of around 7.0%. Vaccines remain less widespread for parasites than for major viral and bacterial diseases, leaving this category smaller despite significant parasite-related economic losses.

Other Infectious Diseases account for approximately 10–12% of revenue and are forecast to expand at around 7.8% CAGR. The above-market growth rate reflects continued development against emerging and less-established animal disease targets.

 

Injectable Vaccines Continue to Dominate Administration Routes

Injectable Vaccines hold approximately 65–70% of the market in 2025 and have a forecast CAGR of around 6.9%. Injection remains deeply established across livestock and companion-animal vaccination and supports many licensed live, inactivated, recombinant and toxoid products.

The category's large revenue share does not mean every high-volume market will remain injection-led. Commercial poultry production and large animal populations increase the value of administration methods that can reduce handling requirements.

Oral Vaccines account for approximately 15–18% of market revenue and are forecast to expand at around 8.0% CAGR. Oral delivery is commercially relevant where individual injection would be costly or impractical, including selected livestock, wildlife and companion-animal applications.

Intranasal Vaccines hold approximately 8–10% share but have the highest growth rate within route of administration at around 9.2% CAGR. Their growth is supported particularly by respiratory disease prevention in companion animals and selected production-animal applications.

Other Routes of Administration represent approximately 5–7% of the market and are expected to grow at around 6.5% CAGR. This includes specialised approaches such as spray, drinking-water and in-ovo vaccination. Their revenue share is relatively small, but some can support extremely high dose volumes in poultry production.

 

Next-Generation Vaccine Technologies Are Gaining Ground at a Rapid but Gradual Pace

Conventional Vaccines account for approximately 55–60% of the veterinary vaccines market in 2025 and have a forecast CAGR of around 5.8%. Their large installed base reflects established live and inactivated products, regulatory familiarity and widespread integration into animal-health programs.

Recombinant Technology-Based Vaccines represent approximately 20–25% of market revenue and are forecast to grow at around 9.0% CAGR. Greater adoption would gradually shift revenue toward products using selected antigens and engineered platforms rather than complete conventional pathogens.

Vector-Based Vaccines account for approximately 10–12% of the market and carry a forecast CAGR of around 8.8%. Poultry is an important commercial setting for this technology because a viral vector can deliver protection against more than one disease through hatchery-based vaccination.

Boehringer Ingelheim's VAXXITEK HVT+IBD+ND, for example, uses an HVT vector and combines protection against Marek's disease, infectious bursal disease and Newcastle disease. The commercial relevance is the consolidation of several disease targets into a single hatchery-stage vaccination rather than the underlying technology alone.

mRNA and Next-Generation Vaccines account for approximately 5–8% of the market in 2025 but carry the fastest supplied technology CAGR at around 12.5%. The current revenue pool is still small compared with conventional vaccines, so the higher growth rate represents a technology-mix shift rather than near-term displacement of established platforms. Regulatory acceptance, manufacturing economics, field durability and disease-specific performance will determine how much of this growth translates into routine commercial use.

 

Distribution Channels Controlling Veterinary Vaccine Sales

Veterinary Hospitals and Clinics account for approximately 40–45% of the market in 2025 and are expected to grow at around 7.0% CAGR. Their leadership is strongly connected to companion-animal vaccination, where veterinarians administer routine and risk-based vaccines during preventive visits.

Veterinary Pharmacies and Retail Stores represent approximately 25–30% of market revenue and have a forecast CAGR of around 6.5%. These channels remain important for farm-animal products and markets where veterinary biologics are distributed through established agricultural retail networks.

Online Platforms account for approximately 8–12% of the market but carry a forecast CAGR of around 11.0%, making them the fastest-growing distribution channel in the supplied segmentation. Growth is likely to be concentrated in markets where regulations permit online ordering and where established cold-chain logistics can support biological products. The need to preserve product integrity means veterinary vaccines cannot follow the same unrestricted e-commerce model as ordinary pet supplies.

Research Institutes and Government Organizations represent approximately 15–18% of the market and are forecast to expand at around 7.8% CAGR. This channel is particularly important for mass livestock campaigns, disease-eradication programs, vaccine banks and emergency outbreak procurement.

 

Which End Users Generate the Largest Commercial Demand

Livestock Farms account for approximately 35–40% of market revenue in 2025 and are expected to grow at around 6.5% CAGR. Their leadership reflects the scale of cattle, swine, sheep and goat populations and the financial consequences of herd-level disease.

Veterinary Clinics and Hospitals represent approximately 25–30% of the market and carry a higher forecast CAGR of around 8.0%. Increasing companion-animal ownership and preventive veterinary spending support repeat vaccine administration through this channel.

Animal Research Institutes account for approximately 10–12% of the market and are expected to expand at around 8.5% CAGR. Their role includes vaccine research, disease surveillance, epidemiological work and evaluation of emerging animal pathogens.

Pharmaceutical and Biotechnology Companies represent approximately 12–15% of end-user demand and carry the highest CAGR within this segmentation at around 9.0%. This reflects increasing investment in recombinant, vector, DNA and next-generation vaccine development as well as reference materials and biologics used within R&D programs.

Government and Regulatory Organizations account for approximately 5–8% of the market and are forecast to grow at around 6.8% CAGR. Their direct revenue share is smaller than that of farms or veterinary clinics, but their influence is disproportionate because national agencies determine vaccination policy, run eradication programs, maintain vaccine reserves and establish biologics licensing requirements.

 

Why Is Poultry Vaccination Becoming More Strategically Important?

Poultry vaccination is primarily driven by the intensity and scale of commercial production systems rather than isolated disease events. High-density farming requires routine protection against key endemic diseases such as Newcastle disease, infectious bronchitis, infectious bursal disease, Marek's disease, and Salmonella, with avian influenza addressed through surveillance and targeted control measures depending on national policy.

Large-scale production systems also influence how vaccines are delivered. Hatchery-based and mass administration methods are widely used because they reduce handling costs and allow uniform coverage across large flocks. This makes poultry vaccination closely linked to industrial production efficiency rather than individual animal treatment decisions.

Ceva illustrates the scale of this segment, reporting 74 billion hatchery-vaccine doses in 2025 across its poultry operations. While this is a company-reported figure, it reflects the very high-volume nature of poultry immunisation compared with other animal categories.

 

How Is Vaccination Supporting the Reduction of Antimicrobial Use?

Vaccination is increasingly integrated into broader animal-health strategies aimed at reducing reliance on antimicrobials. While vaccines do not replace antibiotics in clinical treatment, they reduce the incidence of preventable infectious diseases, thereby lowering the need for therapeutic antimicrobial use.

WOAH’s 2025 antimicrobial-use assessment, covering a large share of global animal biomass, reported an overall 5% decline in antimicrobial use in animals. This trend reflects growing adoption of preventive health measures, including vaccination, improved biosecurity, and herd-health management practices.

From an economic perspective, vaccination decisions are therefore evaluated not only on product cost but on their ability to reduce downstream losses such as mortality, reduced productivity, treatment expenses, and compliance risks associated with antimicrobial stewardship regulations.

 

How Important Is Government Procurement to Veterinary Vaccine Revenue?

Government procurement plays a central role in veterinary vaccine demand, particularly for transboundary and epidemic-prone diseases where coordinated mass vaccination is required. Programs targeting diseases such as foot-and-mouth disease, PPR, rabies, and brucellosis often involve large-scale, centrally funded immunisation campaigns.

For example, Tanzania vaccinated more than 17 million sheep and goats against PPR by October 2025, supported by a national program with a budget of approximately USD 86 million covering multiple priority diseases. Eritrea also conducted a major PPR campaign, vaccinating approximately 2.8 million animals with 3 million doses.

These programs demonstrate that vaccine demand in many regions is shaped by public-sector planning cycles, donor funding, and disease-eradication targets rather than purely commercial farm-level purchasing. WOAH vaccine bank initiatives further support this model by enabling pooled procurement and emergency access to quality-assured vaccines.

 

Who Are the Leading Players Shaping Competition in the Veterinary Vaccines Market?

Zoetis Position in the Veterinary Vaccines Market

Zoetis maintains one of the broadest veterinary-health portfolios across companion animals and livestock. Its Vanguard and Versican vaccine lines cover several canine viral and bacterial diseases, including leptospirosis, Bordetella, canine influenza and parainfluenza, adenovirus, distemper, parvovirus and Lyme disease. The company's wider portfolio also includes cattle, swine and poultry vaccines.

The scale of the parent business supports vaccine development and global distribution. Zoetis reported USD 9.5 billion in 2025 revenue, sells products in more than 100 countries and supports eight core animal species. Companion-animal products represented about 70% of 2025 company revenue, excluding client supply services and human health, while livestock products represented approximately 30%.

That mix gives Zoetis access to relatively high-value veterinary-clinic demand while preserving exposure to large livestock populations. Its competitive strength is therefore based on cross-species portfolio depth rather than dependence on one disease or production system.

 

Merck Animal Health Competes Across Multiple Animal Species

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, operates across cattle, swine, poultry, companion animals and aquaculture. Its livestock vaccine portfolio includes Bovilis/Vista for infectious cattle diseases, M+Pac, Porcilis and Circumvent for swine, and Nobilis/Innovax products in poultry.

The broader Animal Health business recorded USD 6.354 billion in sales in 2025, increasing 8% year over year. Livestock generated USD 3.896 billion and companion animals USD 2.458 billion across all Animal Health products, not vaccines alone.

Merck's competitive position is strengthened by its ability to serve routine companion-animal vaccination, industrial poultry operations, cattle herds and swine production through the same global animal-health infrastructure. This diversification reduces dependence on disease conditions within any one species.

 

Boehringer Ingelheim’s Strengths in Veterinary Vaccination Portfolio

Boehringer Ingelheim has established positions in swine, poultry and companion-animal vaccination. Its INGELVAC franchise includes products against porcine circovirus, Mycoplasma hyopneumoniae, PRRS and other economically important swine diseases. The FLEX family includes combination approaches that allow producers to address several disease targets within consolidated vaccination programs.

In poultry, the VAXXITEK platform is an important vector-vaccine franchise. VAXXITEK HVT+IBD protects against Marek's disease and infectious bursal disease, while VAXXITEK HVT+IBD+ND adds Newcastle disease coverage. Boehringer reports that more than 170 billion birds have been vaccinated with VAXXITEK HVT+IBD since its 2006 launch.

This portfolio gives the company particular exposure to two large-volume vaccine markets: industrial swine and hatchery poultry production.

 

Elanco’s Expansion of Its Veterinary Vaccine Portfolio

Elanco competes in companion-animal and production-animal vaccines through franchises including the Tru Family and AviPro. Its 2025 annual report identifies the Tru Family as primarily vaccine products covering diseases including canine distemper, adenovirus, parvovirus, parainfluenza and leptospirosis as well as several feline infectious diseases. AviPro provides a significant poultry-vaccine presence.

Recent U.S. additions show continued investment in companion-animal vaccination. USDA approved TruCan Ultra B Oral in January 2026 for protection against Bordetella bronchiseptica in dogs.

For Elanco, vaccine expansion provides a recurring preventive-health revenue stream alongside its broader pharmaceutical, parasiticide and farm-animal portfolio.

 

Ceva’s Role in Poultry Vaccines

Ceva Animal Health has positioned poultry vaccination as a major strategic franchise. Its portfolio addresses Newcastle disease, Gumboro disease, infectious bronchitis, coccidiosis, Salmonella, H9 avian influenza and laryngotracheitis.

The company reports 74 billion doses of hatchery vaccines in 2025 and a company-estimated 26% global poultry vaccine market share. The latter should be treated as a company-reported competitive figure rather than an independent market estimate.

Ceva also operates 10 R&D centres and 13 production sites in Europe, including vaccine facilities in France, Germany and the United Kingdom. Its stated objective includes maintaining leadership in poultry vaccines and increasing its role in emerging animal diseases.

Its competitive model is closely tied to hatchery integration and very high dose throughput, which differs substantially from the clinic-based economics of companion-animal vaccination.

 

What Are the Key Forces Driving Veterinary Vaccine Demand Across Global Markets?

North America as a High-Value Veterinary Vaccine Region

North America combines concentrated commercial livestock production with one of the world's most developed companion-animal healthcare sectors. The United States had 86.2 million cattle and calves as of January 1, 2026, including 27.6 million beef cows and 9.57 million milk cows. North America holds the largest regional share in 2025, accounting for approximately 35–38% of the market, and is expected to grow at a CAGR of around 6.5%.

Poultry adds far greater unit volumes. U.S. farms produced 9.40 billion broilers during 2025, alongside 105 billion eggs.

Companion-animal healthcare provides another demand layer, with 95 million U.S. households owning at least one pet in 2025.

These populations support different commercial channels: large livestock accounts, hatcheries and integrated producers purchase high-volume vaccines, while dogs and cats support higher-value recurring vaccination through veterinary clinics. USDA's established biologics licensing system further supports a structured market for branded preventive products.

 

Europe’s Balance Between Established Vaccination and Changing Livestock Demographics

Europe maintains a large livestock population despite gradual declines in several species and accounts for approximately 25–28% share of the veterinary vaccines market in 2025, with a forecast CAGR of around 6.8%. Eurostat reported 131.5 million pigs, 71.6 million bovine animals, 55.3 million sheep and 10.2 million goats in the EU in 2025. Compared with 2024, populations declined by 0.5% for pigs, 0.4% for bovines, 2.2% for sheep and 2.5% for goats.

A shrinking livestock base can moderate dose expansion in mature categories, but changing disease pressure can offset part of that effect. Highly pathogenic avian influenza has remained a prominent risk, with thousands of detections across domestic and wild birds during the 2025–2026 season.

European demand is therefore increasingly shaped by the interaction between stable routine vaccination, emerging-disease preparedness, poultry biosecurity and regulatory decisions over when vaccination should supplement surveillance or culling programs.

 

Asia-Pacific Offers Exceptional Vaccine-Volume Potential

Asia-Pacific is the fastest-growing region, accounting for approximately 22–25% share in 2025 and a CAGR of ~9.0%. It contains some of the world's largest animal populations and several of the widest vaccination-coverage gaps. China ended 2025 with 429.67 million pigs, while official statistics reported 96.08 million cattle and 6.27 billion poultry at year-end. China also slaughtered 18.32 billion poultry during 2025, demonstrating the throughput of its production system.

India adds a strong public-procurement component. Government programs have already delivered more than 110 crore cumulative FMD doses alongside large PPR, brucellosis and classical swine fever vaccination campaigns.

The 2025 global vaccination study identified India as one of the countries where greater cattle vaccination could contribute substantially to reducing global livestock disease burden and identified China among the markets where expanded pig and poultry vaccination could have significant effects.

Asia-Pacific therefore offers large incremental dose potential, although commercial success can depend heavily on government tenders, local manufacturing requirements, affordability and distribution to fragmented farming populations.

 

Latin America's Vaccine Mix Is Changing as Disease-Control Programs Succeed

Latin America remains important because of its large cattle, poultry and swine industries, accounting for approximately 8–10% share in 2025 with a CAGR of ~7.5%. Brazil alone slaughtered a record 42.94 million cattle, 60.69 million pigs and 6.69 billion chickens in 2025.

Brazil also demonstrates how successful disease eradication can change vaccine demand. Its recognition as FMD-free without vaccination removes a large routine use case that historically consumed substantial numbers of doses.

Commercial opportunity therefore shifts toward poultry, swine, reproductive, respiratory and companion-animal diseases as well as emergency preparedness. For livestock-exporting countries, preventive animal health remains economically important because a disease outbreak can interrupt access to overseas markets even after routine vaccination against a particular disease has ended.

 

Government Campaigns Are Particularly Important in the Middle East and Africa

The Middle East and Africa account for 5–7% share in 2025 and are expected to grow at a CAGR of ~7.2%. The region contains large cattle and small-ruminant populations, but access to vaccines and veterinary infrastructure varies considerably between countries, so publicly funded campaigns and international organisations play a larger role in several disease categories.

PPR is a strong example. Tanzania vaccinated more than 17 million small ruminants by October 2025, while Eritrea's 2025 campaign immunised approximately 2.8 million sheep and goats.

Rabies provides another opportunity because WHO reports canine vaccination coverage of only around 30–50% in many parts of Africa and Asia, below the more than 70% level associated with interruption of transmission.

 

What Will Determine the Long-Term Direction of the Veterinary Vaccines Market?

Future veterinary vaccine demand will depend more on vaccination coverage than livestock population growth. Large gaps still exist in major diseases such as FMD, Newcastle disease, classical swine fever and anthrax, meaning improving coverage alone could significantly increase vaccine volumes without needing more animals.

New disease spread is also supporting demand. WOAH (2025) reported that 47% of assessed animal diseases have zoonotic potential and that diseases are increasingly appearing in new regions, highlighting ongoing risks and uneven vaccine access globally.

Technology will continue to shape the market, but adoption remains disease-specific. Growth is faster in DNA, recombinant, vector and mRNA vaccines, while conventional vaccines still dominate current usage, indicating gradual rather than disruptive change.

Government programs remain a key driver. FMD control requires billions of vaccine doses globally, WHO targets 70% dog vaccination coverage for rabies control, and PPR eradication campaigns continue to support large-scale immunisation in Africa and Asia.

Overall, success for vaccine manufacturers will depend less on new product development alone and more on scalable production, regulatory approvals, government partnerships, and the ability to supply both mass livestock programs and clinical veterinary markets.

 

Veterinary Vaccines Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 12.18 Billion
Revenue Forecast in 2032	USD 19.82 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Vaccine Type, By Animal Type, By Disease Type, By Route of Administration, By Technology, By Distribution Channel, By End User, By Geography
By Vaccine Type	Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, DNA Vaccines, Subunit Vaccines, Toxoid Vaccines, Others
By Animal Type	Livestock Animals, Companion Animals, Poultry, Aquaculture Animals
By Disease Type	Viral Diseases, Bacterial Diseases, Parasitic Diseases, Other Infectious Diseases
By Route of Administration	Injectable Vaccines, Oral Vaccines, Intranasal Vaccines, Other Routes
By Technology	Conventional Vaccines, Recombinant Technology-Based Vaccines, Vector-Based Vaccines, mRNA and Next-Generation Vaccines
By Distribution Channel	Veterinary Hospitals and Clinics, Veterinary Pharmacies and Retail Stores, Online Platforms, Research Institutes and Government Organizations
By End User	Livestock Farms, Veterinary Clinics and Hospitals, Animal Research Institutes, Pharmaceutical and Biotechnology Companies, Government and Regulatory Organizations
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Preventive animal health adoption and rising vaccination coverage gaps, increasing livestock disease-control programs and government immunisation initiatives, growing demand for recombinant, vector-based, and next-generation veterinary biologics
Customization Option	Available upon request